Terms: = Prostate cancer AND PAX5, Q02548, 5079, ENSG00000196092, BSAP AND Clinical Outcome
4 results:
1. prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancer.
Paoluzzi M; Losa A; Cerboneschi V; Colosimo C; Fontana N; Mangili P; Mignogna M; Nava L; Ravaglia V
Brachytherapy; 2017; 16(5):1000-1006. PubMed ID: 28642046
[TBL] [Abstract] [Full Text] [Related]
2. The use of prostate-specific antigen testing in men presenting with haematuria.
Bromage SJ; Napier-Hemy RD; Payne SR; Pearce I; McIntyre IG
BJU Int; 2006 Dec; 98(6):1221-4; discussion 1224. PubMed ID: 17034503
[TBL] [Abstract] [Full Text] [Related]
3. Association of pax5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder.
Babjuk M; Soukup V; Mares J; Dusková J; Pecen L; Pesl M; Pavlík I; DvorRcek J
Urology; 2006 Apr; 67(4):756-61. PubMed ID: 16566978
[TBL] [Abstract] [Full Text] [Related]
4. The expression of pax5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.
Babjuk M; Soukup V; Mares J; Dusková J; Sedlácek Z; Trková M; Pecen L; Dvorácek J; Hanus T; Kocvara R; Novák J; Povýsil C
Int Urol Nephrol; 2002; 34(4):495-501. PubMed ID: 14577491
[TBL] [Abstract] [Full Text] [Related]
